Photo from wikipedia
Atomoxetine combined with oxybutynin (Ato‐Oxy) has recently been shown to reduce obstructive sleep apnoea (OSA) severity by >60%. However, Ato‐Oxy also modestly reduced the respiratory arousal threshold, which may decrease… Click to show full abstract
Atomoxetine combined with oxybutynin (Ato‐Oxy) has recently been shown to reduce obstructive sleep apnoea (OSA) severity by >60%. However, Ato‐Oxy also modestly reduced the respiratory arousal threshold, which may decrease sleep quality/efficiency. We sought to investigate the additional effect of zolpidem with Ato‐Oxy on sleep efficiency (primary outcome), the arousal threshold, OSA severity, other standard polysomnography (PSG) parameters, next‐day sleepiness and alertness (secondary outcomes).
Journal Title: Respirology
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!